

Complete this survey as described in the Dialysis Event Protocol.

Instructions: Complete one survey per center. Surveys are completed for the current year. It is strongly recommended that the survey is completed in February of each year by someone who works in the center and is familiar with current practices within the center. Complete the survey based on the actual practices at the center, not necessarily the center policy, if there are differences. For complete instructions on the survey questions, please see the "Instructions for the Outpatient Dialysis Center Practices Survey" document available at: http://www.cdc.gov/nhsn/dialysis/dialysis-event.html#dcf.

Page 1 of 7				
*required to save as complete Facility ID#: *Survey Year:				
	Network#:			
A. Dialysis Center Information				
A.1. G	eneral			
*1.	What is the ownership of your dialysis center? (choose o	 ne)		
	□ Government □ Not for profit	, □ For profit		
*2.	What is the location/hospital affiliation of your dialysis ce	, ,	ng but owned by a	a hospital
*3.	What types of dialysis services does your center offer? (In-center daytime In-center nocturnal hemodialysis hemodialysis	select all that apply)	□ Home hemod	lialysis
*4.	How many in-center hemodialysis stations does your cer	iter have?		
*5.	Is your center part of a group or chain of dialysis centers a. If yes, what is the name of the group or chain?		□ Yes	□ No
*6.	Do you (the person primarily responsible for collecting da patient care in the dialysis center?	ita for this survey) perform	□ Yes	□ No
*7.	Is there someone at your dialysis center in charge of infe a. If yes, which best describes this person? (if >1	person in charge, select all t I practitioner comes to our u		□ No
*8.	Is there a dedicated vascular access nurse/coordinator (center?	either full or part-time) at you	ur 🗆 Yes	□ No
A.2. Is	olation and Screening			
*9.	Does your center have capacity to isolate patients with h	epatitis B?		
	\Box Yes, use hepatitis B isolation room \Box Yes, us	e hepatitis B isolation area	□ No hepatitis I	3 isolation
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 1.75 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other a spect of this collection of information including suggestions for reducing this burden to CDC.				

30333, ATTN: PRA (0920-0666).

CDC 57.500 (Front) Rev 5, V 8.3



A.2. Isolation and Screening (continued)					
*10.	Are patients routinely isolated or (select all that apply)	cohorted for treatment <u>w</u>	ithin your center for any o	of the following cor	nditions?
	□ No, none □ F	lepatitis C	Active tuberculos	is (TB disease)	
	□ Vancomycin-resistant Ente	erococcus (VRE)	Clostridium diffici	le (C. Diff.)	
	Methicillin-resistant Staphy	lococcus aureus (MRSA)) \Box Other, specify:		
*11.	Does your center routinely scree center?	n patients for tuberculosis	s (TB) on admission to yo	our 🗆 Yes	□ No
A.3. P	atient Records				
*12.	Does your center routinely maint assignment?	ain records of patients' he	emodialysis station	□ Yes	□ No
*13.	Does your center routinely maint assignment?	ain records of patients' he	emodialysis machine	□ Yes	□ No
*14.	If a patient from your center was infection contributed to their hos		s your center able to dete	rmine if a bloodstr	eam
	🗆 Always 🛛 Often	□ Sometimes □ I	Rarely 🗆 Never	🗆 N/A – n	ot pursued
*15.	How often is your center able to	obtain a patient's microbi	ology lab records from a	hospitalization?	
	□ Always □ Often	□ Sometimes □ I	Rarely Dever	□ N/A – n	ot pursued
Pleas	e respond to the following quest	tions based on informat	ion from vour center fo	r the first week o	f Februarv
	es to current or most recent Februa				
B. Pat	ient and staff census				
*16.	Was your center operational dur	ing the first week of Febru	uary?	□ Yes	🗆 No
*17.	How many MAINTENANCE, NO first week of February?	N-TRANSIENT dialysis P _	ATIENTS were assigned	I to your center du	ring the
	Of these, indicate the number wh	no received:			
	a. In-center hemodialys	is:			
	b. Home hemodialysis:				
	c. Peritoneal dialysis:				
*18.	How many PATIENT CARE staff week of February? <i>Include only</i> :				
	Of these, how many were in eac	h of the following categor	ies?		
	a. Nurse/nurse assistar	nt:	e. Dietitian:		
	b. Dialysis patient-care	technician:	f. Physicians/phy	sician assistant:	
	c. Dialysis biomedical t	echnician:	g. Nurse practitior	ier:	
	d. Social worker:		h. Other:		
C. Va	cines				
*19.	Of the patients counted in questi	on 17, how many receive	d:		
	a. At least 3 doses of h	epatitis B vaccine (ever)?)		
		accine for the <u>current/mos</u>			
	. ,	INTENANCE, NON-TRANS			auestion
		ived the influenza vaccin			-
	d. The pneumococcal				
*20.	Of your center's MAINTENANCE many received at least 3 doses of	E, NON-TRANSIENT in-ce		nts from question 1	7, how
	-	INTENANCE, NON-TRAN	·	/sis patients from o	question
		ved at least 3 doses of he			



Page 3	
C. Vac	ccines (continued)
*21.	Of the patient care staff members counted in question 18, how many received:
	a. At least 3 doses of hepatitis B vaccine (ever)?
	b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?
*22.	Does your center use standing orders to allow nurses to administer any of the vaccines \Box Yes \Box No
	mentioned above to patients without a specific physician order?
*23.	Which type of pneumococcal vaccine does your center offer to patients ? (choose one)
	□ Polysaccharide (i.e., PPSV23) only
	Conjugate (e.g., PCV13) only
	□ Both polysaccharide & conjugate
	□ Offered, but type unknown
	□ Neither offered
D. He	patitis B and C
	lepatitis B
*24.	Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 17a:
2	a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?
	i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of
	February, how many were positive when first admitted to your center?
	b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during
	the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus
	infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:
	lepatitis C
*25.	Does your center routinely screen hemodialysis patients for hepatitis C antibody (anti- HCV) on admission to your center? (<i>Note: This is NOT hepatitis B core antibody</i>) \Box Ves \Box No
*26.	Does your center routinely screen hemodialysis patients for hepatitis C antibody (anti- \Box Yes \Box No HCV) at any other time?
	a. If yes, how frequently?
	□ Twice annually □ Annually □ Other, specify:
*27.	Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis patients counted in question 17a,
	a. How many were hepatitis C antibody positive in the first week of February?
	i. Of these patients who were hepatitis C antibody positive in the first week of February, how many were positive when first admitted to your center?
	b. How many patients converted from hepatitis C antibody negative to positive during the prior 12 months
	(i.e., in the past year, how many patients had newly acquired hepatitis C infection)? Do not include
	patients who were anti-HCV positive before they were first dialyzed in your center:
E. Dia	alysis Policies and Practices
E.1. D	Nich war Davida
	Dialyzer Reuse
*28.	Does your center reuse dialyzers for any patients?
*28.	
*28.	Does your center reuse dialyzers for any patients?
*28.	Does your center reuse dialyzers for any patients?
*28.	Does your center reuse dialyzers for any patients? □ Yes □ No □ Yes □ Yes □ Yes □ Yes □ No □ Yes □ Yes □ No □ N
*28.	Does your center reuse dialyzers for any patients? □ Yes □ No If yes, a. Where are dialyzers reprocessed? □ Dialyzers are reprocessed at our center only



Page 4 of 7				
E.1. D	Dialyzer Reuse (continued)			
	 c. How is dialyzer header cleaning performed? (select all that apply) Automated machine (e.g., RenaClear® System) Spray device (e.g., ASSIST® header cleaner) Insertion of twist-tie or other instrument to break up clots Disassemble dialyzer to manually clean Other, specify: No separate header cleaning step performed d. Is there a limit to the number of times a dialyzer is used? Yes (indicate number): No limit as long as dialyzer meets certain criteria (e.g., passes pressure leak test, examples of the second se	etc.)		
	Dialysate			
*29.	What type of dialysate is used for in-center hemodialysis patients at your center? (choose one		□ No	
30.	Does your center routinely test dialysate from the patient's machine for culture and endotoxin whenever a patient has a pyrogenic reaction?	□ Yes		
E.3. P	Priming Practices			
*31.	Does your center use hemodialysis machine Waste Handling Option (WHO) ports?	□ Yes	□ No	
*32.	Are any patients in your center "bled onto the machine" (i.e., where blood is allowed to reach or almost reach the prime waste receptacle or WHO port)?	□ Yes	□ No	
E.4. In	njection Practices			
*33.	What form of erythropoiesis stimulating agent (ESA) is most often used in your center?			
	\Box Single-dose vial \Box Multi-dose vial \Box Pre-packaged syringe \Box N/A a. Is ESA from one single-dose vial or syringe administered to more than one patient?	□ Yes	□ No	
*34.	\Box Single-dose vial \Box Multi-dose vial \Box Pre-packaged syringe \Box N/A		-	
*34. *35.	 Single-dose vial Multi-dose vial Pre-packaged syringe N/A a. Is ESA from one single-dose vial or syringe administered to more than one patient? Where are medications most commonly drawn into syringes to prepare for patient administrati At the individual dialysis stations On a mobile medication cart within the treatment area At a fixed location within the patient treatment area (e.g., at nurses' station) At a fixed location removed from the patient treatment area (not a room) In a separate medication room Other, specify:		-	
*35.	 Single-dose vial Multi-dose vial Pre-packaged syringe N/A a. Is ESA from one single-dose vial or syringe administered to more than one patient? Where are medications most commonly drawn into syringes to prepare for patient administrati At the individual dialysis stations On a mobile medication cart within the treatment area At a fixed location within the patient treatment area (e.g., at nurses' station) At a fixed location removed from the patient treatment area (not a room) In a separate medication room Other, specify: Do technicians administer any IV medications or infusates (e.g., heparin, saline) in your 	ion? (cho	ose one)	



Form Approved OMB No. 0920-0666 Exp. Date: 10-31-2016 www.cdc.gov/nhsn

E.6. F	Prevention Activities			
*37.	Has your center participated in any national or regional infection prevention-related initiatives in the past year?	□ Yes	□ No	
	a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply)			
	□ Catheter reduction			
	□ Hand hygiene			
	Bloodstream infection prevention			
	Patient education/engagement for infection prevention			
	□ Increase vaccination rates			
	□ Decrease/improve use of antibiotics			
	Improve general infection control			
	□ Improve culture of safety			
	□ Other, specify:			
38.	Does your center follow <u>CDC-recommended Core Interventions</u> to prevent bloodstream infect hemodialysis patients?	tions in		
	\Box Yes, all \Box Yes, some \Box No, none \Box Don't know			
*39.	Does your center perform hand hygiene audits of staff monthly (or more frequently)?	□ Yes	□ No	
*40.	Does your center perform observations of staff vascular access care and catheter accessing practices quarterly (or more frequently)?	□ Yes	□ No	
*41.	Does your center perform staff competency assessments for vascular access care and catheter accessing annually (or more frequently)?	□ Yes	□ No	
E.7. P	eritoneal Dialysis			
*42.	For peritoneal dialysis catheters , is antimicrobial ointment routinely applied to the exit site c change?	luring dre	ssing	
	□ Yes □ No □ N/A			
	a. If yes, what type of ointment is most commonly used? (choose one)			
	□ Gentamicin □ Bacitracin/polymyxin B (e.g., Polysporin®)			
	□ Mupirocin □ Bacitracin/neomycin/polymyxin B (triple antibiotic)			
	□ Povidone-iodine □ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple)			
	□ Other, specify:			
F. Vas	scular Access			
F.1. G	eneral Vascular Access Information			
*43.	Of the MAINTENANCE, NON-TRANSIENT hemodialysis patients from question 17 (17a + 17	h) how m	anv	
10.	received hemodialysis through each of the following access types during the first week of Feb		iany	
	a. AV fistula			
	b. AV graft			
	c. Tunneled central line			
	 Nontunneled central line Other vascular access device (e.g., catheter-graft hybrid) 			
	e. Other vascular access device (e.g., catheter-graft hybrid)			
	rteriovenous (AV) Fistulas or Grafts			
*44.	Before prepping the fistula or graft site for cannulation, what is the site most often <u>cleansed</u> w	ith? □ Noth	ing	



Page 6					
F.2. A	rteriovenous (AV) Fistulas or Grafts (continued)				
*45.	Before cannulation of a fistula or graft, what is the site most often <u>prepped</u> with? (select the one most commonly used)				
	□ Chlorhexidine without alcohol □ Chlorhexidine with alcohol (e.g., Chloraprep®, Chlorascrub™)				
□ Povidone-iodine (or tincture of iodine)					
	\Box Sodium hypochlorite solution (e.g., ExSept®, Alcavis)				
	□ Other, specify:				
	□ Nothing				
	a. What form of this skin antiseptic is used to prep fistula/graft sites?				
	☐ Multiuse bottle (e.g., poured onto gauze)				
Pre-packaged swabstick/spongestick					
	Pre-packaged pad				
	Other, specify:				
	□ N/A				
*46.	How many of your center's fistula patients undergo buttonhole cannulation?				
	□ All □ Most □ Some □ None				
	If any,				
	a. Which fistula patients undergo buttonhole cannulation?				
	\Box In-center hemodialysis patients only \Box Home hemodialysis patients only \Box Both				
	b. Is antimicrobial ointment (e.g., mupirocin) routinely used at buttonhole cannulation				
	c. If buttonhole cannulation is performed for in-center hemodialysis patients, who most often performs it?				
	□ Nurse □ Patient (self-cannulation) □ Technician □ Other, specify:				
E3 H	lemodialysis Catheters				
*47.	Before accessing the hemodialysis catheter, what are the catheter hubs most commonly prepped with?				
47.	(select one)				
	□ Chlorhexidine without alcohol				
	□ Chlorhexidine with alcohol (e.g., Chloraprep®, Chlorascrub™)				
	□ Povidone-iodine (or tincture of iodine)				
	□ Sodium hypochlorite solution (e.g., Alcavis)				
	□ Other, specify:				
	□ Nothing				
	a. What form of this antiseptic/disinfectant is used to prep the catheter hubs?				
	\Box Multiuse bottle (e.g., poured onto gauze)				
	Pre-packaged swabstick/spongestick				
	Pre-packaged pad				
	□ Other, specify:				
*48.	Are catheter hubs routinely scrubbed after the cap is removed and before accessing the \Box Yes \Box No catheter (or before accessing the catheter via a needleless connector device, if one is used)?				



F.3.	Hemodialysis Catheters (continued)	
<u>+.3.</u> *49.	When the catheter dressing is changed, what is the exit site (i.e., place where the catheter enters the s most commonly prepped with? (select one) □ Alcohol □ Chlorhexidine without alcohol □ Chlorhexidine with alcohol (e.g., Chloraprep®, Chlorascrub TM) □ Povidone-iodine (or tincture of iodine) □ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) □ Other, specify:	kin)
*50.	□ N/A For hemodialysis catheters , is antimicrobial ointment routinely applied to the exit site □ Yes during dressing change?	□ No
	 a. If yes, what type of ointment is most commonly used? (select one) Bacitracin/gramicidin/polymyxin B (Polysporin® Triple) Bacitracin/polymyxin B (e.g., Polysporin®) Bacitracin/neomycin/polymyxin B (triple antibiotic) Other, specify: 	
*51.	What is the job classification of staff members who <u>most often</u> perform hemodialysis catheter care (i.e., catheters or perform exit site care) in your center? (select one)	access
. = 0		-
*52.	Are antimicrobial lock solutions used to prevent hemodialysis catheter infections in your center? Yes, for all catheter patients Yes, for some catheter patients No a. If yes, which lock solution is most commonly used? (select one) No Sodium citrate Taurolidine Gentamicin Ethanol Vancomycin Multi-component lock solution or other, specify:	
*53.	Are needleless closed connector devices used on hemodialysis catheters in your center?	□ No
	If yes, a. What kind? □ Tego® □ Q-Syte™ □ Other, specify: b. For which patients? □ In-center hemodialysis patients only □ Home hemodialysis patients only	 □ Both
*54.	Are any of the following used for hemodialysis catheters in your center? (select all that apply) ☐ Antimicrobial-impregnated hemodialysis catheters ☐ Chlorhexidine dressing (e.g., Biopatch®, Tegaderm™ CHG) ☐ Other antimicrobial dressing (e.g., silver-impregnated) ☐ Antiseptic-impregnated catheter cap (e.g., Curos® Port Protector) ☐ None of the above	
Com	ments:	
Discla	imer: Use of trade names and commercial sources is for identification only and does not imply endorsement.	



Form Approved OMB No. 0920-0666 Exp. Date: 10-31-2016 www.cdc.gov/nhsn